Attached files

file filename
10-Q - FORM 10-Q - Celator Pharmaceuticals Incv384877_10-q.htm
EX-31.2 - EXHIBIT 31.2 - Celator Pharmaceuticals Incv384877_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Celator Pharmaceuticals Incv384877_ex31-1.htm
EX-3.1 - EXHIBIT 3.1 - Celator Pharmaceuticals Incv384877_ex3-1.htm
EX-10.2 - EXHIBIT 10.2 - Celator Pharmaceuticals Incv384877_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Celator Pharmaceuticals Incv384877_ex10-1.htm
EX-4.1 - EXHIBIT 4.1 - Celator Pharmaceuticals Incv384877_ex4-1.htm
EXCEL - IDEA: XBRL DOCUMENT - Celator Pharmaceuticals IncFinancial_Report.xls

 

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350,

 

In connection with the quarterly report of Celator Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

         
Date:  August 7, 2014      

/s/ Scott T. Jackson

        Scott T. Jackson,
        Chief Executive Officer
        (Principal executive officer)
     
Date:  August 7, 2014      

/s/ Fred M. Powell

        Fred M. Powell, Vice President and
        Chief Financial Officer
        (Principal financial and accounting officer)